MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-18-2026
AstraZeneca PLC Revenue 2011-2026 | AZN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 B | 54.1 B | 45.8 B | 44.4 B | 37.4 B | 26.6 B | 24.4 B | 22.1 B | 22.5 B | 23 B | 24.7 B | 26.1 B | 25.7 B | 28 B | 33.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.7 B | 22.1 B | 33.1 B |
Quarterly Revenue AstraZeneca PLC
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.22 B | - | - | - | 6.28 B | - | - | - | 5.82 B | - | - | - | 5.16 B | - | - | - | 5.05 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.22 B | 5.05 B | 6.1 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
5 K | - | -19.68 % | $ 18.4 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
958 M | $ 21.96 | -0.68 % | $ 3.64 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
8.04 M | $ 1.02 | -0.49 % | $ 428 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Aligos Therapeutics
ALGS
|
2.19 M | $ 6.4 | 4.4 % | $ 63.3 M | USA |
 |
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
3.09 M | - | 17.91 % | $ 11.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.4 M | - | -52.27 % | $ 4.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 21.41 | 1.9 % | $ 1 B | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |
 |
Kazia Therapeutics Limited
KZIA
|
1.07 M | $ 12.26 | 3.72 % | $ 1.62 B |  Australia |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 105.46 | -0.09 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.08 | 0.25 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 23.26 | 1.75 % | $ 2.96 B | USA |
 |
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.44 | -5.88 % | $ 383 M | Britain |
 |
BioXcel Therapeutics
BTAI
|
642 K | $ 1.06 | -3.64 % | $ 12.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
30.2 M | - | - | $ 35.4 M | USA |
 |
Cabaletta Bio
CABA
|
0.006 | $ 2.95 | -3.28 % | $ 296 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 2.91 | -1.36 % | $ 4.79 M | Israel |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |